Items related to Horizons in World Cardiovascular Research. Volume 26...

Horizons in World Cardiovascular Research. Volume 26 (Horizons in World Cardiovascular Research Series) - Hardcover

 
9798891134423: Horizons in World Cardiovascular Research. Volume 26 (Horizons in World Cardiovascular Research Series)

Synopsis

This book is a compilation of ten chapters in Cardiovascular research from around the world. Chapter One starts off with ß -blockers and their use in the prevention of acute cardiac events. Chapter Two focuses on the emerging roles of extracellular chaperones and some of their associated cochaperones in cardiovascular disease and the appealing prospect for the development of novel pharmacotherapeutic strategies against the disease by targeting these complexes. The authors in Chapter Three review of previous trials suggest that coronary revascularization significantly reduces mortality and myocardial infarction rates in patients with stable coronary artery disease and moderate-to-severe ischemia. In Chapter Four, the authors provide diagnosis, risk factors and the management of heart failure with preserved ejection fraction. The objective of Chapter Five is to include the most current findings on the cellular pathophysiology of HFpEF and HFpEF-related comorbidities that are being discovered, which might eventually lead to more patient-specific medicines with clinical significance. In Chapter Six the authors describe the short-term clinical courses of seven hemodialysis patients receiving sacubitril-valsartan, as well as the long-term clinical courses of two anuric hemodialysis patients with reduced left ventricular ejection fractions after aortic valve replacement for aortic stenosis who showed improvement in cardiac function after the administration of sacubitril-valsartan. Chapter Seven speaks about the current issues in total arterial revascularization. Chapter Eight goes on to cover the advances in technology and interpretation software that have occurred in recent years. Chapter Nine highlights the significant transformations that monitoring systems have endured over history with details on the recording technique. The goal of the last chapter was to assess the prevalence of asymptomatic heart failure with preserved ejection fraction (HFpEF) in subjects at high risk of developing heart failure and to define the diagnostic accuracy of (N-terminal pro-B-type natriuretic peptide (NT-pro BNP) assay compared with echocardiography in this setting.

"synopsis" may belong to another edition of this title.

Buy Used

Condition: As New
Unread book in perfect condition...
View this item

£ 1.96 shipping within U.S.A.

Destination, rates & speeds

Search results for Horizons in World Cardiovascular Research. Volume 26...

Stock Image

Unknown, Unknown
ISBN 13: 9798891134423
New

Seller: GreatBookPrices, Columbia, MD, U.S.A.

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Condition: New. Seller Inventory # 47613257-n

Contact seller

Buy New

£ 182.05
Convert currency
Shipping: £ 1.96
Within U.S.A.
Destination, rates & speeds

Quantity: 3 available

Add to basket

Stock Image

Eleanor H. Bennington
Published by Nova Science Publishers Inc, 2024
ISBN 13: 9798891134423
New Hardcover

Seller: Grand Eagle Retail, Mason, OH, U.S.A.

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Hardcover. Condition: new. Hardcover. This book is a compilation of ten chapters in Cardiovascular research from around the world. Chapter One starts off with ss -blockers and their use in the prevention of acute cardiac events. Chapter Two focuses on the emerging roles of extracellular chaperones and some of their associated cochaperones in cardiovascular disease and the appealing prospect for the development of novel pharmacotherapeutic strategies against the disease by targeting these complexes. The authors in Chapter Three review of previous trials suggest that coronary revascularization significantly reduces mortality and myocardial infarction rates in patients with stable coronary artery disease and moderate-to-severe ischemia. In Chapter Four, the authors provide diagnosis, risk factors and the management of heart failure with preserved ejection fraction. The objective of Chapter Five is to include the most current findings on the cellular pathophysiology of HFpEF and HFpEF-related comorbidities that are being discovered, which might eventually lead to more patient-specific medicines with clinical significance. In Chapter Six the authors describe the short-term clinical courses of seven hemodialysis patients receiving sacubitril-valsartan, as well as the long-term clinical courses of two anuric hemodialysis patients with reduced left ventricular ejection fractions after aortic valve replacement for aortic stenosis who showed improvement in cardiac function after the administration of sacubitril-valsartan. Chapter Seven speaks about the current issues in total arterial revascularization. Chapter Eight goes on to cover the advances in technology and interpretation software that have occurred in recent years. Chapter Nine highlights the significant transformations that monitoring systems have endured over history with details on the recording technique. The goal of the last chapter was to assess the prevalence of asymptomatic heart failure with preserved ejection fraction (HFpEF) in subjects at high risk of developing heart failure and to define the diagnostic accuracy of (N-terminal pro-B-type natriuretic peptide (NT-pro BNP) assay compared with echocardiography in this setting. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Seller Inventory # 9798891134423

Contact seller

Buy New

£ 184.07
Convert currency
Shipping: FREE
Within U.S.A.
Destination, rates & speeds

Quantity: 1 available

Add to basket

Stock Image

Unknown, Unknown
ISBN 13: 9798891134423
Used

Seller: GreatBookPrices, Columbia, MD, U.S.A.

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Condition: As New. Unread book in perfect condition. Seller Inventory # 47613257

Contact seller

Buy Used

£ 185.23
Convert currency
Shipping: £ 1.96
Within U.S.A.
Destination, rates & speeds

Quantity: 3 available

Add to basket

Stock Image

Unknown, Unknown
ISBN 13: 9798891134423
Used

Seller: GreatBookPricesUK, Woodford Green, United Kingdom

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Condition: As New. Unread book in perfect condition. Seller Inventory # 47613257

Contact seller

Buy Used

£ 179.75
Convert currency
Shipping: £ 15
From United Kingdom to U.S.A.
Destination, rates & speeds

Quantity: 3 available

Add to basket

Stock Image

Unknown, Unknown
ISBN 13: 9798891134423
New

Seller: GreatBookPricesUK, Woodford Green, United Kingdom

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Condition: New. Seller Inventory # 47613257-n

Contact seller

Buy New

£ 221.11
Convert currency
Shipping: £ 15
From United Kingdom to U.S.A.
Destination, rates & speeds

Quantity: 3 available

Add to basket

Stock Image

Eleanor H. Bennington
Published by Nova Science Publishers Inc, 2024
ISBN 13: 9798891134423
New Hardcover

Seller: AussieBookSeller, Truganina, VIC, Australia

Seller rating 5 out of 5 stars 5-star rating, Learn more about seller ratings

Hardcover. Condition: new. Hardcover. This book is a compilation of ten chapters in Cardiovascular research from around the world. Chapter One starts off with ss -blockers and their use in the prevention of acute cardiac events. Chapter Two focuses on the emerging roles of extracellular chaperones and some of their associated cochaperones in cardiovascular disease and the appealing prospect for the development of novel pharmacotherapeutic strategies against the disease by targeting these complexes. The authors in Chapter Three review of previous trials suggest that coronary revascularization significantly reduces mortality and myocardial infarction rates in patients with stable coronary artery disease and moderate-to-severe ischemia. In Chapter Four, the authors provide diagnosis, risk factors and the management of heart failure with preserved ejection fraction. The objective of Chapter Five is to include the most current findings on the cellular pathophysiology of HFpEF and HFpEF-related comorbidities that are being discovered, which might eventually lead to more patient-specific medicines with clinical significance. In Chapter Six the authors describe the short-term clinical courses of seven hemodialysis patients receiving sacubitril-valsartan, as well as the long-term clinical courses of two anuric hemodialysis patients with reduced left ventricular ejection fractions after aortic valve replacement for aortic stenosis who showed improvement in cardiac function after the administration of sacubitril-valsartan. Chapter Seven speaks about the current issues in total arterial revascularization. Chapter Eight goes on to cover the advances in technology and interpretation software that have occurred in recent years. Chapter Nine highlights the significant transformations that monitoring systems have endured over history with details on the recording technique. The goal of the last chapter was to assess the prevalence of asymptomatic heart failure with preserved ejection fraction (HFpEF) in subjects at high risk of developing heart failure and to define the diagnostic accuracy of (N-terminal pro-B-type natriuretic peptide (NT-pro BNP) assay compared with echocardiography in this setting. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. Seller Inventory # 9798891134423

Contact seller

Buy New

£ 268
Convert currency
Shipping: £ 27.40
From Australia to U.S.A.
Destination, rates & speeds

Quantity: 1 available

Add to basket